We demonstrated for the first time an outstanding ability of rosiglitazone to mediate a profound enhancement of LA-12-induced apoptosis associated with activation of mitochondrial pathway in human colon cancer cells. This effect was preferentially observed in the G1 cell cycle phase, independent on p53 and PPARγ proteins, and accompanied with significant changes of selected Bcl-2 family protein levels. Further stimulation of cooperative synergic cytotoxic action of rosiglitazone and LA-12 was demonstrated in the cells deficient for PTEN, where mitochondrial apoptotic pathway was more stimulated and G1-phase-associated dying was reinforced. Our results suggest that combined treatment with rosiglitazone and LA-12 might be promising anticancer strategy in colon-derived tumours regardless of their p53 status, and also favourable in those defective in PTEN function.

Department of Clinical and Molecular Pathology Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

Department of Cytokinetics Institute of Biophysics Academy of Sciences of the Czech Republic v v i Brno Czech Republic

Department of Cytokinetics Institute of Biophysics Academy of Sciences of the Czech Republic v v i Brno Czech Republic; Department of Animal Physiology and Immunology Institute of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic

INCELL Corporation LLC San Antonio Texas United States of America

Institute of Clinical Biochemistry and Diagnostics University Hospital Hradec Kralove Hradec Kralove Czech Republic

Platinum Pharmaceuticals a s Brno Czech Republic

Zobrazit více v PubMed

Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications -a review. Nutr J. 2014;13:17. Epub 2014/02/15. doi: 1475-2891-13-17 [pii] 10.1186/1475-2891-13-17 . PubMed DOI PMC

Siersbaek R, Nielsen R, Mandrup S. PPARγin adipocyte differentiation and metabolism- novel insights from genome-wide studies. FEBS Lett. 2010;584(15):3242–9. Epub 2010/06/15. doi: S0014-5793(10)00492-8 [pii] 10.1016/j.febslet.2010.06.010 . PubMed DOI

Brockman JA, Gupta RA, Dubois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology. 1998;115(5):1049–55. Epub 1998/10/31. doi: S0016508598004521 [pii]. . PubMed

Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J. PPARγ controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene. 2003;22(27):4186–93. Epub 2003/07/02. 10.1038/sj.onc.1206530 1206530 [pii]. . PubMed DOI

Lefebvre M, Paulweber B, Fajas L, Woods J, McCrary C, Colombel JF, et al. Peroxisome proliferator-activated receptor γ is induced during differentiation of colon epithelium cells. J Endocrinol. 1999;162(3):331–40. Epub 1999/09/01. 10.1677/joe.0.1620331 . PubMed DOI

Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001;22(9):1379–83. Epub 2001/09/05. 10.1093/carcin/22.9.1379 . PubMed DOI

Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med. 1998;4(9):1046–52. Epub 1998/09/12. 10.1038/2030 . PubMed DOI

Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, Hisatake J, et al. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res. 2001;61(13):5307–10. Epub 2001/06/30. . PubMed

Chiu SJ, Hsaio CH, Tseng HH, Su YH, Shih WL, Lee JW, et al. Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells. Biochem Biophys Res Commun. 2010;394(3):774–9. Epub 2010/03/17. doi: S0006-291X(10)00519-X [pii] 10.1016/j.bbrc.2010.03.068 . PubMed DOI

Zhang YQ, Tang XQ, Sun L, Dong L, Qin Y, Liu HQ, et al. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor γ. World J Gastroenterol. 2007;13(10):1534–40. Epub 2007/04/28. 10.3748/wjg.v13.i10.1534 . PubMed DOI PMC

Kim YH, Jung EM, Lee TJ, Kim SH, Choi YH, Park JW, et al. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med. 2008;44(6):1055–68. Epub 2008/01/01. doi: S0891-5849(07)00797-6 [pii]10.1016/j.freeradbiomed.2007.12.001 . PubMed DOI

Miao R, Xu T, Liu L, Wang M, Jiang Y, Li J, et al. Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line. Exp Ther Med. 2011;2(3):413–7. Epub 2011/05/01. 10.3892/etm.2011.227 etm-02-03-0413 [pii]. . PubMed DOI PMC

Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, et al. Synergy between PPARγ ligands and platinum-based drugs in cancer. Cancer Cell. 2007;11(5):395–406. Epub 2007/05/08. doi: S1535-6108(07)00066-9 [pii] 10.1016/j.ccr.2007.02.025 . PubMed DOI PMC

Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, et al. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res. 2008;14(20):6478–86. Epub 2008/10/18. doi: 14/20/6478 [pii] 10.1158/1078-0432.CCR-08-1128 . PubMed DOI PMC

Tikoo K, Kumar P, Gupta J. Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer. 2009;9:107. Epub 2009/04/10. doi: 1471-2407-9-107 [pii] 10.1186/1471-2407-9-107 . PubMed DOI PMC

Zak F, Turanek J, Kroutil A, Sova P, Mistr A, Poulova A, et al. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J Med Chem. 2004;47(3):761–3. Epub 2004/01/23. 10.1021/jm030858+ . PubMed DOI

Kozubik A, Vaculova A, Soucek K, Vondracek J, Turanek J, Hofmanova J. Novel anticancer platinum(IV) complexes with adamantylamine: their efficiency and innovative chemotherapy strategies modifying lipid metabolism. Met Based Drugs. 2008;2008:417897 Epub 2008/04/17. 10.1155/2008/417897 . PubMed DOI PMC

Kozubik A, Horvath V, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, et al. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol. 2005;69(3):373–83. Epub 2005/01/18. doi: S0006-2952(04)00646-X [pii]10.1016/j.bcp.2004.09.005 . PubMed DOI

Horvath V, Blanarova O, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, et al. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol. 2006;102(1):32–40. Epub 2005/12/21. doi: S0090-8258(05)01006-1 [pii]10.1016/j.ygyno.2005.11.016 . PubMed DOI

Roubalova E, Kvardova V, Hrstka R, Borilova S, Michalova E, Dubska L, et al. The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Invest New Drugs. 2010;28(4):445–53. Epub 2009/06/06. 10.1007/s10637-009-9270-4 . PubMed DOI

Svihalkova-Sindlerova L, Foltinova V, Vaculova A, Horvath V, Soucek K, Sova P, et al. LA-12 overcomes confluence-dependent resistance of HT-29 colon cancer cells to Pt (II) compounds. Anticancer Res. 2010;30(4):1183–8. Epub 2010/06/10. doi: 30/4/1183 [pii]. . PubMed

Vondalova Blanarova O, Jelinkova I, Hyrslova Vaculova A, Sova P, Hofmanova J, Kozubik A. Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells. Cell Prolif. 2013;46(6):665–76. Epub 2013/10/15. 10.1111/cpr.12061 . PubMed DOI PMC

Vondalova Blanarova O, Jelinkova I, Szoor A, Skender B, Soucek K, Horvath V, et al. Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway. Carcinogenesis. 2011;32(1):42–51. Epub 2010/11/03. doi: bgq220 [pii] 10.1093/carcin/bgq220 . PubMed DOI

Jelinkova I, Safarikova B, Vondalova Blanarova O, Skender B, Hofmanova J, Sova P, et al. Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway. Biochem Pharmacol. 2014;92(3):415–24. Epub 2014/10/07. doi: S0006-2952(14)00557-7 [pii] 10.1016/j.bcp.2014.09.013 . PubMed DOI

Kvardova V, Hrstka R, Walerych D, Muller P, Matoulkova E, Hruskova V, et al. The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Mol Cancer. 2010;9:147. Epub 2010/06/17. doi: 1476-4598-9-147 [pii] 10.1186/1476-4598-9-147 . PubMed DOI PMC

Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M. Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anticancer Drugs. 2006;17(2):201–6. Epub 2006/01/24. doi: 00001813-200602000-00012 [pii]. . PubMed

Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282(5393):1497–501. Epub 1998/11/20. . PubMed

Lee C, Kim JS, Waldman T. PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res. 2004;64(19):6906–14. Epub 2004/10/07. doi: 64/19/6906 [pii] 10.1158/0008-5472.CAN-04-1767 . PubMed DOI PMC

Moyer MP, Manzano LA, Merriman RL, Stauffer JS, Tanzer LR. NCM460, a normal human colon mucosal epithelial cell line. In Vitro Cell Dev Biol Anim. 1996;32(6):315–7. Epub 1996/06/01. . PubMed

Vaculova A, Hofmanova J, Soucek K, Andera L, Kozubik A. Ethanol acts as a potent agent sensitizing colon cancer cells to the TRAIL-induced apoptosis. FEBS Lett. 2004;577(1–2):309–13. Epub 2004/11/06. doi: S0014579304012426 [pii] 10.1016/j.febslet.2004.10.013 . PubMed DOI

Elrod HA, Sun SY. PPAR and apoptosis in cancer. PPAR Res. 2008;2008:704165 Epub 2008/07/11. 10.1155/2008/704165 . PubMed DOI PMC

Dai Y, Qiao L, Chan KW, Zou B, Ma J, Lan HY, et al. Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. Int J Cancer. 2008;122(12):2858–63. Epub 2008/03/21. 10.1002/ijc.23443 . PubMed DOI

Zhu Y, Hoell P, Ahlemeyer B, Krieglstein J. PTEN: a crucial mediator of mitochondria-dependent apoptosis. Apoptosis. 2006;11(2):197–207. Epub 2006/02/28. 10.1007/s10495-006-3714-5 . PubMed DOI

Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, et al. Activation of Akt/protein kinase B overcomes a G(2)/M cell cycle checkpoint induced by DNA damage. Mol Cell Biol. 2002;22(22):7831–41. Epub 2002/10/23. PubMed PMC

Hrstka R, Powell DJ, Kvardova V, Roubalova E, Bourougaa K, Candeias MM, et al. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anticancer Drugs. 2008;19(4):369–79. Epub 2008/05/06. 10.1097/CAD.0b013e3282f7f50000001813-200804000-00005 [pii]. . PubMed DOI

Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPAR-independent signal pathways. Mol Cancer Ther. 2006;5(2):430–7. Epub 2006/03/01. doi: 5/2/430 [pii] 10.1158/1535-7163.MCT-05-0347 . PubMed DOI

He Q, Pang R, Song X, Chen J, Chen H, Chen B, et al. Rosiglitazone suppresses the growth and invasiveness of SGC-7901 gastric cancer cells and angiogenesis in vitro via PPARγ dependent and independent mechanisms. PPAR Res. 2008;2008:649808 Epub 2008/09/24. 10.1155/2008/649808 . PubMed DOI PMC

Qiao L, Dai Y, Gu Q, Chan KW, Ma J, Lan HY, et al. Loss of XIAP sensitizes colon cancer cells to PPARγ independent antitumor effects of troglitazone and 15-PGJ2. Cancer Lett. 2008;268(2):260–71. Epub 2008/05/15. doi: S0304-3835(08)00279-6 [pii] 10.1016/j.canlet.2008.04.003 . PubMed DOI

Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ. Cancer Res. 2005;65(4):1561–9. Epub 2005/03/01. doi: 65/4/1561 [pii] 10.1158/0008-5472.CAN-04-1677 . PubMed DOI

Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer. 2006;6:53. Epub 2006/03/08. doi: 1471-2407-6-53 [pii] 10.1186/1471-2407-6-53 . PubMed DOI PMC

Burgermeister E, Seger R. PPARγ and MEK Interactions in Cancer. PPAR Res. 2008;2008:309469 Epub 2008/07/04. 10.1155/2008/309469 . PubMed DOI PMC

Role of miR-653 and miR-29c in downregulation of CYP1A2 expression in hepatocellular carcinoma

Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10

Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells